Translatome analysis reveals altered serine and glycine metabolism in T-cell acute lymphoblastic leukemia cells by Kampen, K.R. (Kim) et al.
ARTICLE
Translatome analysis reveals altered serine
and glycine metabolism in T-cell acute
lymphoblastic leukemia cells
Kim R. Kampen 1,12, Laura Fancello 1,12, Tiziana Girardi 1, Gianmarco Rinaldi 2,3, Mélanie Planque2,3,
Sergey O. Sulima1, Fabricio Loayza-Puch 4, Benno Verbelen1, Stijn Vereecke 1, Jelle Verbeeck1,
Joyce Op de Beeck1, Jonathan Royaert1, Pieter Vermeersch5, David Cassiman 6, Jan Cools7,8,
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Somatic ribosomal protein mutations have recently been described in cancer, yet their impact
on cellular transcription and translation remains poorly understood. Here, we integrate mRNA
sequencing, ribosome footprinting, polysomal RNA sequencing and mass spectrometry
datasets from a mouse lymphoid cell model to characterize the T-cell acute lymphoblastic
leukemia (T-ALL) associated ribosomal RPL10 R98S mutation. Surprisingly, RPL10 R98S
induces changes in protein levels primarily through transcriptional rather than translation
efﬁciency changes. Phosphoserine phosphatase (PSPH), encoding a key serine biosynthesis
enzyme, was the only gene with elevated transcription and translation leading to protein
overexpression. PSPH upregulation is a general phenomenon in T-ALL patient samples,
associated with elevated serine and glycine levels in xenograft mice. Reduction of PSPH
expression suppresses proliferation of T-ALL cell lines and their capacity to expand in mice.
We identify ribosomal mutation driven induction of serine biosynthesis and provide evidence
supporting dependence of T-ALL cells on PSPH.
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Somatic mutations in genes encoding ribosomal proteinswere recently described in 10–35% of patients with differentleukemias and solid tumor types1. Whereas inactivating
mutations and deletions in ribosomal protein L5 (RPL5, protein
also known as uL18) and L22 (RPL22, eL22) are common in
multiple tumor types2–9, lesions affecting RPL10 (uL16) have
mainly been described in pediatric T-cell acute lymphoblastic
leukemia (T-ALL), with additional rare mutations in multiple
myeloma4,5. RPL10 shows an intriguing mutational hotspot:
almost all RPL10 mutant T-ALL patients carry the same arginine-
to-serine missense mutation at residue 98 (R98S)5,10.
We recently performed quantitative mass spectrometry on an
isogenic lymphoid Ba/F3 B-cell model expressing theWT or R98S
mutant allele of RPL1011. This allowed to compare expression
levels of the 5557 most abundant proteins and revealed an
upregulation of 178 (3%) and a downregulation of 68 (1%) pro-
teins in the R98S cells (p < 0.01). In particular, this proteomics
screen demonstrated RPL10 R98S-associated overexpression of
the JAK-STAT signaling cascade and cell metabolism changes.
We proposed differences in ribosomal frameshifting, proteasome
activity, and JAK-STAT transcript levels as mechanisms con-
tributing to the upregulation of the JAK-STAT cascade11. RPL10
R98S cells also show a cell survival advantage due to upregulation
of internal ribosomal entry site (IRES)-driven translation of the
anti-apoptotic factor BCL212. However, a systematic genome-
wide investigation of the effects of RPL10 R98S on the tran-
scriptome and translatome has not been performed. Additionally,
it is unclear to what extent previously detected quantitative
proteomics changes were caused by RPL10 R98S-associated
transcriptional, translational, and post-translational modulation.
For this purpose, we now perform mRNA sequencing and
sequencing of ribosome-associated RNA (ribosome footprinting
or RPF-seq)13 using the same isogenic Ba/F3 cell model, and
integrate these datasets with our previously described quantitative
proteomics and polysomal RNA sequencing datasets11. Ribosome
footprinting provides nucleotide resolution mapping of active
translation and allows to detect changes in translational efﬁciency
(TE), based on the number of ribosome-protected fragment
(RPF) reads for an mRNA, which reﬂects the average number of
ribosomes bound to this mRNA. Polysomes (or polyribosomes)
refer to multiple ribosomes bound to a single mRNA because of
efﬁcient translation. Polysomal RNA sequencing involves
sequencing of polysome-attached mRNA, providing a second
independent method to assess translation efﬁciencies. Our inte-
grated multi-omics analyses reveal signiﬁcant transcriptional
changes associated with RPL10 R98S, which can explain up to
47.15% of the observed protein changes. Changes in TE are only
observed for a small set of genes, including phosphoserine
phosphatase (Psph). Psph, which encodes a key enzyme in serine
biosynthesis, is consistently upregulated at both transcriptional
and translational levels in RPL10 R98S cells, and is one of the
strongest upregulated proteins associated with this mutation.
RPL10 R98S cells display elevated serine and glycine biosynthesis
in metabolic tracer analyses, and higher levels of these metabolites
are present in conditioned culture media of RPL10 R98S cells.
Interestingly, overexpression of PSPH occurs in the majority of T-
ALL patient samples, and PSPH targeting can suppress human T-
ALL expansion in vivo. Our results thus support dependence of
T-ALL cells on the serine biosynthesis enzyme PSPH.
Results
RPL10 R98S induces distinct ribosome footprinting signatures.
We previously described that introduction of the RPL10 R98S
mutation in lymphoid cells causes signiﬁcant protein abundance
changes in 4% of identiﬁed proteins11. These changes may be due
to gene expression regulation at the transcriptional, translational,
and/or post-translational level. In order to better delineate the
causes of detected protein changes in RPL10 R98S cells, we gen-
erated a ribosome footprinting dataset (sequencing of ribosome-
protected mRNA fragments, RPF-seq) together with an mRNA-
sequencing dataset of the same cells in this study. These two
datasets were integrated with our previously published datasets of
polysomal RNA sequencing and its matched mRNA sequencing,
with another mRNA sequencing dataset and with the quantitative
proteomics obtained from the same set of Ba/F3 RPL10 WT and
R98S clones (Fig. 1a).
Ribosome footprinting was highly reproducible across three
biological replicates (Supplementary Fig. 1) and ribosome
footprints presented the expected length and triplet periodicity
(Fig. 1b, c). The nucleotide resolution of ribosome footprinting
allows investigating ribosome occupancy around the start and
stop codons, but metagene plots across the most represented
transcripts in the ribosome footprinting dataset did not reveal
general defects in translation initiation or termination in RPL10
R98S cells (Fig. 1d). However, principal component analysis on
ribosome footprints clearly separated the RPL10 R98S from WT
samples (Fig. 1e).
RPL10 R98S causes extensive transcriptional changes. Differ-
ences in ribosome footprinting signatures can be caused by
altered available cellular mRNA levels (transcriptional changes),
by altered numbers of translating ribosomes associated with the
cellular mRNA (altered TE), or by a combination of both. We
started by looking into transcriptional changes and noticed that
differences in mRNA levels correlated well with differences in
ribosome footprints in RPL10 R98S versus WT cells (Pearson’s
coefﬁcient on log2-transformed data: 0.76) (Fig. 2a). Principal
component analysis of the mRNA-sequencing dataset matching
the ribosome footprinting separated the RPL10 R98S and RPL10
WT samples (Fig. 2b). The same was also observed for two
additional mRNA-sequencing datasets that were previously gen-
erated from our isogenic Ba/F3 cell model (mRNA sequencing
matching polysomal RNA sequencing11 and an additional inde-
pendent mRNA sequencing12) (Supplementary Fig. 2A). Com-
paring these datasets, 368 genes were consistently upregulated
and 421 genes downregulated in RPL10 R98S cells, which were
included for further analyses (Supplementary Data 1, Supple-
mentary Fig. 2B). No enriched pathways were found in the
upregulated mRNAs, whereas downregulated mRNAs were
enriched for pathways involved in signaling, vesicle transport, cell
adhesion, cell migration, and protein localization (Supplementary
Data 2). We hypothesized that differences in expression levels or
activity of transcription factors may play a role in the observed
transcriptional changes. Therefore, we used iRegulon to predict
regulators which may explain the observed differential tran-
scriptional program in RPL10 R98S cells14. Many of the predicted
transcription factors have a known role in hematopoiesis and
leukemia development (Ikzf2, Pbx3, and Hoxa13 for upregulated
genes and Fos, Nkx2-2, Gata2 for downregulated genes, Supple-
mentary Data 3 and 4, Fig. 2c, d). Ikzf2 (Helios), a predicted
regulator of upregulated transcripts, was itself overexpressed at
the mRNA and protein levels, as conﬁrmed by immunoblots in
RPL10 R98S Ba/F3 cells, as well as in Jurkat T-ALL cells in which
the RPL10 R98S mutation was introduced using CRISPR-Cas9
technology (Fig. 2e). Of interest, Nkx2-2 and Nkx2-1 were pre-
dicted as transcriptional regulators of the underexpressed mRNAs
in RPL10 R98S cells. Both proteins have been implicated in T-
ALL pathogenesis, and RPL10 R98S mutations signiﬁcantly co-
occur with NKX2-1 lesions in T-ALL10,15. However, NKX2-1
protein expression was undetectable in RPL10 WT or R98S Ba/F3
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cells. We thus conclude that RPL10 R98S causes transcriptional
changes of hematopoietic transcription factor target genes, with
upregulation of Ikzf2 being consistently observed in two inde-
pendent RPL10 R98S cells models.
RPL10 R98S alters TE of an mRNA subset. Ribosome foot-
printing is commonly used to estimate TE, deﬁned as RPF counts
normalized to mRNA levels. We searched for differences in TE
between RPL10 R98S and RPL10 WT using the statistics provided
by the Babel R package16.
To obtain a more complete view, we also considered TE
changes obtained from our previously published polysomal RNA
sequencing in the same Ba/F3 cell model11. A total of 121
protein-coding genes showed a different TE according to
ribosome footprinting and/or polysomal RNA sequencing
(Supplementary Data 5 and 6, Supplementary Fig. 3A–C). Genes
with insufﬁcient sequencing coverage (<10 reads per sample in
ribosome footprinting and/or polysomal RNA sequencing and
in their matching mRNA) were excluded, resulting in 67 genes
with a statistically signiﬁcant TE change between RPL10 R98S
and WT (Fig. 3a). These 67 genes showed enrichment, among
others, for cell metabolism and cell-signaling pathways (Supple-
mentary Fig. 5D). In particular, the Jak-Stat-signaling cascade,
which we previously described to be overexpressed on protein
level upon RPL10 R98S expression11, was enriched amongst genes
with higher TE in RPL10 R98S cells (adjP= 2.40e−08, n= 6,
Supplementary Fig. 3D, Supplementary Data 2). Moreover,
ribosome biogenesis (KEGG, adjP= 0.0009, n= 2) and rRNA
transcription (transcription from RNA polymerase I promoter,
GO, adjP= 2.29e−02, n= 3) were enriched among genes with
lower TE in RPL10 R98S cells (Supplementary Fig. 3D,
Supplementary Data 2), which is in agreement with the fact that
RPL10 R98S has previously been associated with ribosome
assembly defects5,17.
RPL10 R98S-associated protein changes are mainly due to
transcriptional modulation. We compared the list of 67 differ-
entially translated genes with protein measurements from our
quantitative mass spectrometry dataset to verify if TE changes
resulted in consistent protein level changes (Fig. 3a). For 31 out of
the 67 differentially translated genes, protein measurements were
available. Only Psph, belonging to the cell metabolism category of
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genes, showed a statistically signiﬁcant protein change (p= 0.001,
4.7-fold upregulation) consistent with its TE change (Fig. 3a, b).
As 246 proteins presented signiﬁcantly altered expression levels
(p < 0.01, t-test, n= 3 biologically independent RPL10 WT and
R98S Ba/F3 clones) between RPL10 R98S and WT in the mass
spectrometry dataset11, we investigated whether the remaining
differentially expressed proteins were associated with consistent
changes in mRNA expression rather than TE. For Psph (0.4%) we
observed an upregulation both in mRNA expression and in TE,
whereas 47.2% (n= 116) of the protein changes were only asso-
ciated with signiﬁcant upregulation or downregulation of mRNA
expression levels, in agreement with our observation of extensive
transcriptional changes associated with RPL10 R98S (Fig. 3c,
Supplementary Data 1). For 52.4% (n= 129), no consistent sig-
niﬁcant change in mRNA or TE was observed (Fig. 3c, Supple-
mentary Data 7). Linear regression models conﬁrmed that
changes in mRNA levels and in TE according to either ribosome
footprinting or polysomal RNA sequencing can only explain
between 36.3% and 38.9% of variability for the 246 signiﬁcant
protein changes (R2= 0.363 and 0.389, Supplementary
Fig. 4A–E). Combining mRNA and TE changes from ribosome
footprinting and polysomal RNA sequencing slightly improved
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the regression models (R2= 0.403, AIC= 502.19, Supplementary
Fig. 4A+F), suggesting that these datasets provide com-
plementary information.
The gene sets with a signiﬁcant TE change, as identiﬁed by
ribosome footprinting or polysomal RNA sequencing analysis,
showed little overlap (Supplementary Fig. 3A). On the other
hand, genome-wide changes in ribosome footprint counts and in
polysomal mRNA counts correlated well (Pearson correlation on
log2-transformed data: 0.62) (Fig. 3d) and each had a comparable
correlation with protein changes (signiﬁcant and non-signiﬁcant
changes considered; Pearson correlation on log2-transformed
data: 0.38 and 0.42, Fig. 3e). In conclusion, combining ribosome
footprinting and polysomal RNA sequencing improved our
capacity to explain RPL10 R98S associated protein expression
changes, which were primarily imposed by transcriptional rather
than translational changes, along with yet undeﬁned mechanisms.
Psph upregulation in RPL10 R98S cells induces serine/glycine
synthesis. Analysis of the RPL10 R98S-associated transcriptome,
translatome, and proteome revealed a consistent upregulation
of Psph transcription (p < 0.001, fold change (FC)= 3.8–6.5),
TE (FDR= 0.006, FC= 2.5) and protein expression (p= 0.014,
FC= 4.7) (Supplementary Fig. 5). Psph encodes phosphoserine
phosphatase and catalyzes the last step of the serine synthesis
pathway in which 3-phosphoserine is dephosphorylated to serine
(Fig. 4a). RPL10 R98S-associated transcriptional upregulation of
PSPH was conﬁrmed in Ba/F3 clones and in a Jurkat T-ALL cell
model expressing RPL10 R98S (Supplementary Fig. 6). Induction
of PSPH TE was further supported by polysomal qRT-PCR
analysis showing a shift of the distribution of ribosome-bound
PSPH mRNA towards the most actively translated polysomal
fractions in RPL10 R98S cells as compared to WT cells (Supple-
mentary Fig. 7). These data thus collectively support increased
overall PSPH translation by increased mRNA expression as well
as TE. Immunoblot analysis conﬁrmed a >10-fold and 1.5-fold
upregulation of Psph protein expression in RPL10 R98S Ba/F3
and Jurkat clones, respectively (Fig. 4b, c, p < 0.001 for Ba/F3; p=
0.032 for Jurkat). Furthermore, we investigated Psph protein
expression in hematopoietic cell cultures obtained by serial
replating of lineage negative bone marrow (lin- BM) cells from
Rpl10 R98S knock-in mice11. Psph was upregulated in the RPL10
R98S as compared to RPL10 WT bone marrow cells (p= 0.004)
(Fig. 4d). To evaluate the functional impact of Psph protein
expression changes, intracellular serine and glycine concentra-
tions were measured. The overall serine and glycine pools were
signiﬁcantly elevated in Ba/F3 RPL10 R98S clones (p < 0.05,
Fig. 4e). Furthermore, 13C6-Glucose tracer analysis showed that
synthesis of M+ 2/M+ 3 serine and M+ 2 glycine from 13C-
Glucose was increased in RPL10 R98S as compared to WT Ba/F3
clones (p < 0.01 and p < 0.05) (Fig. 4e). Conversion of serine into
glycine is a bidirectional reaction, which is catalyzed by Shmt1 in
the cytosol or Shmt2 in the mitochondria (Fig. 4a). The increases
in serine species containing only 2 (M+ 2 serine) labeled carbons
in the 13C6-Glucose tracer analysis support high serine/glycine
exchange in RPL10 R98S cells. Validation experiments showed no
consistent changes in any of the enzymes involved in serine/
glycine synthesis other than PSPH (Supplementary Fig. 8, Sup-
plementary Data 8). Despite high PSPH expression in RPL10 WT
Jurkat T-ALL cells, introduction of the RPL10 R98S mutation in
this cell model also induced elevated total labeled serine (M+ 1,
M+ 2, and M+ 3 together) and glycine (M+ 1 and M+ 2)
contribution from 13C6-Glucose (Supplementary Fig. 9A and B,
total labeled serine p= 0.020, total labeled glycine p= 0.007).
Interestingly, the 13C6-Glucose tracing also revealed signiﬁcantly
increased M+ 6, and a tendency of elevated M+ 7, M+ 8, and
M+ 9 AMP, ADP, ATP and GMP, GDP, GTP purines, sup-
porting incorporation of serine and glycine-derived carbons into
purines (Fig. 4f, Supplementary Fig. 10). This was not observed
for pyrimidine bases TMP, CMP, and UMP. These results sup-
port a general increase of PSPH protein expression in RPL10
R98S cell models that is associated with an enhanced de novo
serine/glycine biosynthesis to generate purines. The higher serine/
glycine production in Rpl10 R98S cells was not associated with
elevated de novo protein synthesis (Fig. 4g). Serine catabolism to
glycine is an already known mechanism of oxidative cancers to
generate formate, which is then incorporated into purines18,19. In
line with these ﬁndings, Rpl10 R98S mutant lin− BM cells pre-
sented enhanced formate levels as compared to WT lin− BM cells
(Fig. 4h, p= 0.008). In conclusion, we show in multiple isogenic
and primary cell models that RPL10 R98S enforces PSPH-driven
serine/glycine synthesis to fuel formate and purine synthesis.
Most primary T-ALL samples express elevated PSPH mRNA
levels. Next, we explored the relevance of our ﬁndings for patients
with T-ALL in general, independent of the RPL10 R98S mutation.
Analysis of mRNA-sequencing data from human T-ALL cell lines
Fig. 3 Signiﬁcant TE changes identiﬁed by ribosome footprinting or polysomal RNA sequencing. a Circular heatmap representing the protein-coding genes with
signiﬁcant changes in TE (Babel, FDR < 0.1, Z-test with Benjamini–Hochberg correction, n= 3 biologically independent RPL10 WT and R98S Ba/F3 clones),
identiﬁed by polysomal RNA sequencing (outer circle) or ribosome footprinting (middle circle). Corresponding protein changes, when available, are shown in
the inner circle. The color scale represents the signed p-value associated to the change (which indicates both signiﬁcance and direction of the change).
Statistically signiﬁcant changes are indicated by a star (*) and correspond to FDR < 0.1 for TE changes (Babel, Z-test with Benjamini–Hochberg correction, n= 3
biologically independent RPL10 WT and R98S Ba/F3 clones) and p-value < 0.01 for protein change (T-test on normalized spectra from quantitative mass
spectrometry, n= 3 biologically independent RPL10 WT and R98S Ba/F3 clones). Only genes with at least 10 aligned ribosome footprints or polysomal RNA
reads and at least 10 reads in the corresponding mRNA sequencing dataset for each sample are considered. Genes not passing this threshold or genes with no
corresponding protein mass spectrometry measurement are indicated as not available. b Representation of the normalized RPFs for RPL10 WT and R98S Ba/F3
clones aligned to PSPH 5’ untranslated region (5’UTR), coding sequence (CDS, in yellow), and 3’UTR (ENSMUST00000031399). Four arrows indicate the
upstream ORFs (positions: 10–369; 373–447; 463–561; 613–681) as predicted by altORFev (10.1093/bioinformatics/btw736). These plots contain pooled data
from three RPL10 WT versus three R98S Ba/F3 clones. c Percentages of signiﬁcant protein changes (quantitative mass spectrometry, T-test, p-value < 0.01)
associated with signiﬁcant mRNA changes (differential expression analysis by DESeq2, two-sided Wald test with Benjamini–Hochberg correction, FDR < 0.1,
n= 3 biologically independent RPL10 WT and R98S Ba/F3 clones) and/or with signiﬁcant TE changes (Babel, Z-test with Benjamini–Hochberg correction, FDR <
0.1, n= 3 biologically independent RPL10 WT and R98S Ba/F3 clones) or neither. Both ribosome footprinting and polysomal RNA sequencing matching mRNA-
sequencing datasets were considered for changes in mRNA levels. Changes in TE identiﬁed by ribosome footprinting and/or polysomal RNA sequencing were
both considered. d Scatterplot representing the correlation between the log2-transformed fold change (RPL10 R98S versus RPL10 WT) in RPF counts and the
log2-transformed fold change in polysomal RNA-sequencing counts. e Scatterplots representing the correlation between the log2-transformed fold changes
(RPL10 R98S versus RPL10 WT) in RPF counts (on the left) or polysomal RNA-sequencing counts (on the right) and the log2-transformed fold change in
normalized protein spectral counts. Cor Pearson correlation coefﬁcient
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and primary patient samples20 showed that all cell lines displayed
3- to 18-fold higher PSPH mRNA levels as compared to the
normal thymus control (Supplementary Fig. 11A). Similarly, the
majority of T-ALL patient samples showed elevated PSPH mRNA
expression, with the two-patient samples harboring the RPL10
R98Smutation in the analyzed cohort showing upregulation by 8-
fold (TUG7_R98S) and 13-fold (R6_R98S) (Supplementary
Fig. 11A). In agreement with this, analysis of publicly available
mRNA expression databases supported a general upregulation of
PSPH in T-ALL samples, with an average 2.6-fold upregulation of
PSPH mRNA in T-ALL patient samples versus normal bone
marrow controls (Fig. 5a). Other serine biosynthesis enzymes
PHGDH and PSAT1 were also upregulated by 3.2-fold and 3.4-
fold in T-ALL, as opposed to glycine synthesis enzyme SHMT2
that was unchanged between T-ALL samples and normal bone
marrow controls (Fig. 5a). These analyses show that mRNA
expression levels of enzymes belonging to the serine synthesis
pathway are generally elevated in T-ALL, with the most sig-
niﬁcant increase for PSPH. In line with this ﬁnding, PSPH protein
levels were elevated in primary T-ALL patient sample xenografts
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as compared to normal bone marrow and acute myeloid leukemia
samples (Supplementary Fig. 11B).
Increased circulating serine and glycine levels can enhance the
survival of supportive cells. The upregulation of serine bio-
synthesis enzymes in T-ALL samples encouraged us to further
explore the functional contribution of serine biosynthesis in T-
ALL. We measured levels of serine biosynthesis metabolites in
plasma samples from mice that had reached the disease end stage
upon xenografting with human pediatric T-ALL patient samples.
While metabolite ion exchange chromatography revealed the
elevation of (phospho-)serine in some plasma samples collected
after xenografting, it was mainly glycine that was elevated
(Fig. 5b). In agreement with this, conditioned media (CM) taken
from RPL10 R98S Ba/F3 cell cultures that have reached their
growth plateau contained 15–20 μM more serine and glycine as
compared to CM from RPL10 WT cultures (Fig. 5c). 13C6-glucose
tracing analysis of conditioned media revealed that RPL10 R98S
clones secreted more labeled serine and glycine metabolites in the
medium (Fig. 5d). Moreover, the RPL10 R98S mutant cells
showed a tendency towards less uptake of serine and glycine from
the culture medium (Fig. 5e). Parental Ba/F3 cells showed a better
cell survival when provided with CM from RPL10 R98S Ba/F3
cells (Fig. 5f). As serine was completely consumed in the media of
Ba/F3 WT cell cultures at their growth plateau (Fig. 5c), we
reasoned that concentrations of 20 μM serine might be causal for
the survival beneﬁt in RPL10 WT cells upon stimulation with CM
from RPL10 R98S cells. Indeed, addition of 20 μM serine to
exhausted WT cultures could mimic the effects observed from
addition of RPL10 R98S CM. Moreover, the survival beneﬁt
associated with CM from RPL10 R98S cells could not be further
enhanced by the addition of another 20 µM of serine (Fig. 5f).
These data suggest that by enhancing their de novo serine/glycine
synthesis, the RPL10 R98S cells can stimulate survival of other
cells by excreting part of the synthesized serine/glycine and by
reducing their uptake. This is consistent with the observation that
T-ALL xenografted mice presented elevated serine/glycine levels
in their blood plasma. Therefore, we reasoned that such eleva-
tions in serine and glycine levels in the circulation/CM might also
beneﬁt cells that form the protective niche for the maintenance of
leukemia cells. To test this hypothesis, the effects of serine and
glycine addition on the survival kinetics of mouse hematopoietic
cells were measured. Mouse bone marrow stromal cells showed a
prolonged cell survival when serine was added, while myeloid
cells showed an extended survival in the presence of glycine
(Fig. 5g, p < 0.05 for multiple data points). Altogether, these
results suggest that the upregulation of serine biosynthesis genes
in T-ALL cells facilitates intrinsic de novo serine and glycine
synthesis, resulting in elevated levels of these metabolites in the
blood. Increased serine and glycine availability can promote the
survival of healthy cells, such as cells from the bone marrow
niche, which can in turn beneﬁt leukemia cells by providing a
supportive microenvironment for engraftment and expansion.
T-ALL cells depend on de novo serine synthesis. Cancer cells
undergo metabolic rewiring that makes them dependent on
endogenously produced serine21. The observation that PSPH was
overexpressed in our T-ALL cell model, as well as in T-ALL
patient samples urged us to investigate to what extent leukemic
cells are dependent on PSPH expression for their proliferation
and/or survival. The effects of 40–50% reduction of PSPH protein
levels by two different PSPH targeting shRNAs were explored in
three independent T-ALL cell lines (Supplementary Fig. 12,
Fig. 6a). PSPH knockdown reduced cell proliferation of all tested
T-ALL cell lines (Fig. 6b). Consistently, non-transduced leukemic
cells expanded over time, resulting in a loss of mCherry-labeled
PSPH knockdown cells (Supplementary Fig. 13). DND41, the cell
line with highest PSPH mRNA expression levels, was the least
affected by PSPH knockdown, presumably due to relatively high
residual PSPH levels (Fig. 6a). Apoptosis was induced in KE37,
but not in RPMI8402 and DND41 (Fig. 6b). As PSPH targeting
mainly affected the expansion of T-ALL cells and induced limited
apoptosis, we hypothesized that PSPH knockdown interfered
with one of the cell cycle checkpoints. CDK2 phosphorylation at
threonine 160 (Thr-160) is required for cell cycle progression
through the S-phase of the cell cycle22, and this Thr-160 phos-
phorylation was decreased in T-ALL cell lines KE37 and
RPMI8402 upon PSPH knockdown (Fig. 6c). In line with these
data, we observed a signiﬁcant decrease in cell cycle progression
in PSPH knockdown T-ALL cells (Fig. 6d, Supplementary
Fig. 14A). We found evidence for increased serine catabolism to
formate in R98S cells (Fig. 4h), and hypothesized that PSPH
might be an important factor controlling catabolism to formate in
order to enhance purine synthesis. Accordingly, PSPH knock-
down T-ALL cells presented 20–40% reduced formate NAD(P)H
levels (Fig. 6e). In contrast, de novo protein synthesis was not
reduced in PSPH knockdown T-ALL cells (Fig. 6f, Supplementary
Fig. 14B), suggesting that altered serine/glycine metabolism due
to altered PSPH levels mainly drives formate generation and
purine synthesis.
To analyze the effects of reducing PSPH levels in vivo, mice
were injected with freshly transduced and >90% viable T-ALL
cells containing either scrambled control or PSPH shRNA
plasmids (Fig. 7A, Supplementary Fig. 15A). In vivo leukemia
progression induced by KE37 T-ALL cells was comparable to that
observed when injecting primary patient-derived T-ALL cells,
with leukemia engraftment to the bone marrow and inﬁltration
into the spleen (Fig. 7b+d). All KE37 xenografted animals
developed leukemia. However, PSPH knockdown cells showed a
signiﬁcantly lower expansion potential in the bone marrow, as
Fig. 4 Upregulation of Psph in RPL10 R98S cells induces serine/glycine synthesis. a Schematic overview of serine/glycine synthesis branching from
glycolysis. b, d Immunoblot analysis of Psph in several RPL10 WT and R98S cell models: b Ba/F3 lymphoid cells, c Jurkat T-ALL cells, and d lineage negative
(lin−) bone marrow (BM) cells. Quantiﬁcations below the blots include data from at least three biological replicates. e Total intracellular serine and glycine
concentrations in RPL10 WT and R98S Ba/F3 cells. Eight independent Ba/F3 RPL10 WT clones versus six RPL10 R98S clones were analyzed. f Metabolic
tracer analysis using 13C6-glucose, measuring serine/glycine and associated tracing into purine precursors AMP and GMP. For serine/glycine
measurements, we combined two independent experiments comparing eight Ba/F3 RPL10 R98S WT clones with six RPL10 R98S clones. Six independent Ba/
F3 RPL10 WT clones versus ﬁve RPL10 R98S clones are analyzed for AMP and GMP. g Flow cytometry analysis of de novo protein synthesis by O-propargyl-
puromycin (OPP) incorporation for Rpl10 WT and R98S lin− BM cells. Results from triplicate samples from two independent mouse donors are shown and
relative mean ﬂuorescent intensity (MFI) is plotted. h Relative formate NAD(P)H levels in the bone marrow of WT and R98S mutant mice. Formate NAD
(P)H levels were subtracted from background NAD(P)H levels and corrected for protein input. The box-plots include combined results of two independent
experiments comparing threeWT versus three R98S mutant BM CFC assay samples, derived from independent donor mice. All box-plots show the median
and error bars deﬁne data distribution. Statistical analysis *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001. #clone IDs of Ba/F3 and Jurkat. p-values
were calculated using a two-tailed Student’s t-test. Color codes: gray indicates RPL10 WT control clones and blue indicates RPL10 R98S clones
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well as in the spleen in comparison to scrambled control cells, as
supported by reduced percentages of mCherry-positive shPSPH
containing cells for both hairpins compared to the scrambled
shRNA (Fig. 7b+d). Total spleen weights of leukemic mice were
signiﬁcantly reduced in shPSPH#2 xenografted animals (Fig. 7c).
This experiment was also performed for the RPMI8402 T-ALL
cell line using shPSPH#1. RPMI8402 leukemia cells mainly
inﬁltrated the spleen (Supplementary Fig. 15B+D), and bone
marrow analysis was therefore less informative. In mice
xenografted with RPMI8402, the reduction of PSPH levels also
impaired the capacity of the cells to inﬁltrate and expand in the
spleen (Supplementary Fig. 15C and D). In line with these data,
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X12 primary T-ALL PDX cells transduced with shPSPH#1 and
shPSPH#2 were not able to expand in vivo in NSG mice, while
scrambled shRNA X12 T-ALL cells were detectable in the blood,
bone marrow, and spleen (Supplementary Fig. 16). These results
further support that T-ALL cells depend on high PSPH
expression for leukemic expansion and highlight PSPH as
therapeutic target in T-ALL. Normal cells are likely not
responsive to PSPH targeting due to their general low expression
of PSPH and their low dependence on endogenous serine
synthesis21.
Discussion
The impact of cancer associated somatic ribosome defects on
cellular transcription and translation remains poorly understood.
To address this, we generated mRNA sequencing, ribosome
footprinting, polysomal RNA sequencing, and quantitative mass
spectrometry datasets from an isogenic RPL10 R98S Ba/F3 cell
model. This multi-omics approach revealed that the RPL10 R98S
ribosomal defect is associated with signiﬁcant transcriptional and
translational changes. However, while most of the protein chan-
ges detected by mass spectrometry were supported by transcrip-
tional regulation, ~50% of protein changes could not be explained
by differences in mRNA or TE levels, suggesting post-
translational regulation mechanisms. We previously identiﬁed
RPL10 R98S-associated changes in proteasome composition and
activity levels11 and we speculate that differences in protein sta-
bility may explain part of these protein changes. In agreement
with this, we found Jak1 among those protein changes that are
unexplained by transcriptional or translational changes (Supple-
mentary Data 7). Jak1 is a protein which we previously reported
to be upregulated in RPL10 R98S cells due to increased protein
stability11.
An in silico analysis of RPL10 R98S-associated transcriptional
changes identiﬁed several transcription factors involved in
hematopoietic differentiation that may drive such gene expression
changes. This is particularly relevant in T-ALL, which is typically
associated with a block in hematopoietic T-cell lineage develop-
ment due to aberrant expression of hematopoietic transcription
factors23. Ikaros2/Helios was overexpressed in our RPL10 R98S
Ba/F3 and Jurkat cell models, whereas inactivation of Helios has
been described in B- and T-ALL24,25. However, Helios is also
known to be involved in regulatory T-cell development, similar to
STAT5 that was also upregulated in RPL10 R98S cells26,27. Reg-
ulatory T-cells facilitate suppression of the immune system and
are therefore often increasingly found in cancers28. One could
speculate that the observed upregulation of Helios and Stat5
expression may allow leukemic cells to suppress immune sur-
veillance. Another predicted transcriptional regulator of
underexpressed mRNAs in RPL10 R98S cells was Fos. FOS can
dimerize with JUN family proteins to form the AP-1 oncogenic
transcription factor complex. Human RPL10 (previously named
QM) and its chicken homolog (previously named Jif-1, jun
interacting factor 1) negatively regulate c-JUN by inhibiting its
DNA binding and transactivation29–31. In particular, RPL10 was
reported to compete with FOS for the same binding domain on
JUN29. These data may indicate an impact of the R98S mutation
on the extra-ribosomal regulation of JUN by RPL10.
Besides transcriptional changes, our ribosome footprinting and
polysomal RNA sequencing datasets also allowed to detect a
subset of genes with RPL10 R98S-associated differences in TE.
The subset of differentially translated genes identiﬁed by the two
techniques showed a poor overlap, which may be due to technical
and/or analytical biases. Only recently has the comparison
between the two techniques been fully addressed32. Ribosome
footprinting measures TE based on average ribosome occupancy
of mRNAs whereas polysomal RNA sequencing measures this
feature based on polysomal association of an mRNA. While only
ribosomes associated to the canonical coding sequence are con-
sidered when estimating TE in ribosome footprinting, poly-
cistronic mRNAs may be associated with the polysomal fraction
even if ribosomes are bound to alternative rather than canonical
open-reading frames (ORFs), which cannot be distinguished in
polysomal RNA sequencing. Differences in sample preparation
may also play a role, because polysomal RNA sequencing only
uses the polysomal fraction, whereas ribosome footprinting also
includes monosomes. Although polysomes are considered to
contain the actively translating ribosomes, recent studies in S.
cerevisiae revealed that monosomes are elongating and translate
nonsense-mediated mRNA decay (NMD) targets, upstream
ORFs, short ORFs and low abundance regulatory proteins33. In
light of these differences, it is particularly useful to have access to
both types of datasets in the same model. The fact that combining
ribosome footprinting and polysomal RNA sequencing improved
the prediction of protein changes, suggests that these techniques
are complementary.
Serine biosynthesis enzyme PSPH showed the most consistent
RPL10 R98S-associated change in gene expression, with tran-
scriptional upregulation in all available mRNA datasets, increased
TE according to ribosome footprinting, and increased association
to the most actively translating polysomal fractions according to
qRT-PCR. PSPH also represented one of the strongest upregu-
lated proteins by mass spectrometry, and was the only gene
whose changes at the transcriptional and TE level could be
conﬁrmed by a signiﬁcant difference in protein expression. The
serine biosynthesis pathway recently became of interest to the
cancer research community, as a subset of triple negative breast
cancers harbor an ampliﬁcation of PHGDH leading to a
Fig. 5 T-ALL-derived circulating serine and glycine can facilitate a cell survival beneﬁt for leukemia supporting cells. a PHGDH, PSAT1, PSPH, and SHMT2
Affymetrix MAS 5.0 mRNA expression levels obtained from the R2 AMC genomics analysis and visualization platform (Meijerink dataset). Data were
extracted and re-plotted comparing normal bone marrow (green, NBM, n= 7) control samples and pediatric T-ALL samples (orange, n= 117). bMetabolite
levels measured by ion exchange chromatography in plasma samples from control mice (green) and mice xenografted with the indicated T-ALL samples
(orange). Metabolites are reported in μmol/L. From left to right, the boxplots represent phospho-serine, serine and glycine. X# indicates the T-ALL PDX
sample ID. Control mice n= 4 and PDX mice X11 n= 5, X12 n= 5, X13 n= 5, X14 n= 2, X15 n= 5. RPL10 R98S cases are indicated in blue. c Ion exchange
chromatography determined serine and glycine levels in pooled conditioned media from either RPL10 WT or R98S Ba/F3 clones (n= 2 independent
biological measurements of pooled CM n= 3). Data are represented as mean ± standard deviation. d 13C6-Glucose tracing of labeled serine and glycine
released in the conditioned media of six Ba/F3 RPL10 WT clones versus ﬁve R98S clones. e Glycine and serine uptake rates comparing n= 6 Ba/F3 RPL10
WT clones versus n= 5 R98S clones. f Absolute viable cell counts of parental Ba/F3 cells to which conditioned medium (CM) taken from RPL10 WT or
R98S cells was added, with or without addition of 20 μM serine. g Cell culture conﬂuency plots illustrating the survival of bone marrow stromal cells and
myeloid macrophages in presence and absence of 400 μM serine or glycine. Data are represented as mean ± standard deviation. All box-plots show the
median and error bars deﬁne data distribution. Statistical analysis *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001. p-Values were calculated using a
two-tailed Student’s t-test
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Fig. 6 PSPH suppression blocks the expansion potential of human T-ALL cells in vitro. a Fluorescent immunoblot analysis of PSPH protein levels in KE37,
DND41, and RPMI8402 cells upon knockdown of PSPH using two independent shRNAs, with the quantiﬁcation of three independent blots on the right.
b Left: growth curves representing proliferation of PSPH knockdown cells over time for T-ALL cell lines KE37, DND41, and RPMI8402. Middle: Proliferation
index which was calculated based on pooling of at least three individual data points from the left plot in order to quantify the effects of PSPH shRNA
interference on T-ALL cell proliferation. Right: Apoptosis in PSPH knockdown cells (three averaged data points). Data are represented as mean ± standard
deviation. c Immunoblot analysis of phosphorylated CDK2 at threonine 160. d Left histograms: BrdU incorporation or PI cell cycle ﬂow cytometry analysis
of representative scrambled control and PSPH knockdown T-ALL cell lines. Right: Quantiﬁcation of the percentage cycling cells in cultures of scrambled,
shPSPH#1, and shPSPH#2 KE37, DND41, and RPMI8402 T-ALL cells. For technical reasons, some T-ALL lines were only analyzed by either BrdU or PI cell
cycle analysis, and at least in two independent experiments per sample. e Relative formate-derived NAD(P)H levels in scrambled control and PSPH
knockdown T-ALL cells (combined results for KE37, RPMI8402, DND41, X12). Background NAD(P)H levels were subtracted from formate-derived NAD(P)
H levels and the data were corrected for protein input. The box-plots include combined results of two independent experiments. f Flow cytometry analysis
of de novo protein synthesis by O-propargyl-puromycin (OPP) incorporation. Relative protein synthesis as shown in the ﬁgure was calculated as shPSPH#1
and shPSPH#2 OPP MFI relative to scrambled control cells for KE37, RPMI8402, and DND41. All box-plots show the median and error bars deﬁne data
distribution. Statistical analysis *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001. p-values were calculated using a two-tailed Student’s t-test
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corresponding overexpression of this serine biosynthesis
enzyme34,35. PHGDH ampliﬁed breast cancer cell lines are
dependent on de novo serine synthesis for their proliferation36.
High tumor cell-speciﬁc PSPH expression was observed in
hepatocellular carcinoma and associated with inferior patient
survival21. Constitutive PSPH expression has been shown to
induce tumor progression in an in vivo model of hepatocellular
carcinoma, while shRNA targeting of PSPH reduced the tumor
burden in the same model21. Here, we show that de novo serine/
glycine synthesis is increased via PSPH upregulation upon the
introduction of the T-ALL-speciﬁc RPL10 R98S mutation. Con-
ditioned medium of RPL10 R98S cells contained higher serine
and glycine levels, and we showed that exposure of wild type cells
to extra serine or glycine promotes their proliferation and sur-
vival. Whilst the lack of a dose-dependent effect of serine addition
to RPL10 R98S-conditioned Ba/F3 medium does not necessarily
imply that another factor is involved, this remains a possibility.
Furthermore, our results support that enhanced reversible serine/
glycine turnover within the leukemia cells mainly functions to
fuel formate generation, which can serve for purine synthesis of
T-ALL cells (Fig. 8). In contrast to naïve T-cells, activated T-cells
also show increased serine catabolism into formate for purine
synthesis37. While normal T-cells are mainly dependent on exo-
genous uptake of serine/glycine from the environment, RPL10
R98S cells show a high dependence on PSPH-driven endogenous
serine/glycine synthesis for the generation of formate to fuel
purine synthesis37. High expression levels of PSPH was not
unique to RPL10 R98S-positive T-ALL samples, supporting that
other unknown mechanisms contribute to high PSPH expression
in T-ALL. Therefore, the RPL10 R98S mutation may not be the
sole event identifying patients that may beneﬁt from PSPH
inhibition.
In addition to PSPH upregulation, we describe a general
induction of serine synthesis enzymes in T-ALL samples.
PHGDH and PSPH are not located in regions that are recurrently
ampliﬁed in T-ALL10,38. However, increased serine synthesis has
been described in Cyclin D3:CDK4/6 complex driven T-ALL as a
side effect from inhibition of glycolysis enzymes 6-
phosphofructokinase (PFKP) and pyruvate kinase M2 (PKM2),
causing redirection of glycolytic intermediates into the pentose
phosphate (PPP) and serine pathways39. Targeting the serine
pathway in T-ALL may represent an attractive therapeutic
approach. For example, it has previously been shown that the
CDK4/6 inhibitor palbociclib indirectly inhibits the serine path-
way by increasing the endogenous activity of PFKP and PKM239.
In our RPL10 R98S model, it can be hypothesized that cells might
be sensitive to palbociclib-induced activation of PFKP and PKM2
to counteract the enhanced expression and activity of the PSPH-
driven serine synthesis in this T-ALL subset.
In conclusion, we describe the importance of PSPH in human
T-ALL, which can be transcriptionally and translationally upre-
gulated by the introduction of the ribosomal RPL10 R98S muta-
tion. Our data emphasize a regulatory function of a ribosomal
protein mutation in the metabolic rewiring of leukemic cells.
Methods
Datasets. All RNA sequencing and proteomics datasets were generated from
isogenic mouse lymphoid Ba/F3 cells engineered to express theWT or R98Smutant
allele of the human RPL10 gene11, with three independent WT and three R98S cell
clones analyzed in each experiment.
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Fig. 7 PSPH suppression blocks the expansion potential of human T-ALL cells in vivo. a Left: Schematic experimental overview of the in vivo set-up to test
the effects of PSPH knockdown on leukemia engraftment and progression by tail vein injection of 1*106 scrambled control, shPSPH#1, or shPSPH#2-
transduced cells 24 h after initial transduction. Right: immunoblot conﬁrmation of PSPH knockdown in the cells that were injected in the mice. b Percentage
of mCherry-expressing cells in the bone marrow of leukemic mice as determined by ﬂow cytometry. c Spleen weights of the leukemic mice at disease end
stage. Data are shown as individual data points accompanied by the median and whiskers representing data distribution. d Percentage of mCherry-
expressing cells in the spleen of leukemic mice as determined by ﬂow cytometry. All box-plots show the median and error bars deﬁne data distribution.
Statistical analysis: *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001. p-values were calculated using a two-tailed Student’s t-test
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Polysomal RNA sequencing and matched total mRNA sequencing. Up to three
polysome associated and matched total mRNA sequencing libraries were generated
for each of the three monoclonal Ba/F3 cultures expressing either WT or R98S
RPL1011. Brieﬂy, polysomal fractions (fractions containing at least two ribosomes,
see Supplementary Fig. 17) were pooled and RNA was extracted using the phenol/
chloroform method with inclusion of an extra washing step with 70% ethanol.
Libraries were generated from total mRNA and polysome bound RNA using the
TruSeq Stranded mRNA Sample Prep Kit (Illumina) and were sequenced on an
Illumina 500 instrument.
Supplementary total mRNA sequencing dataset. Five million cells were treated
with cycloheximide (CHX, 100 μg/ml) for 5 min, followed by RNA isolation using
the Maxwell 16 LEV simplyRNA Cells Kit (Promega). Sequencing libraries were
generated using the TruSeq Stranded mRNA Sample Prep Kit (Illumina) and were
sequenced on an Illumina HiSeq 2500 instrument.
Ribosome footprinting and matched total mRNA sequencing. Two hundred
million cells were treated with CHX (100 μg/ml) for 5 min and lysed in buffer (20
mM Tris–HCl, pH 7.8, 100 mM KCl, 10 mM MgCl2, 1% Triton X-100, 2 mM DTT,
100 μg/ml CHX, and complete protease inhibitor). Lysates were centrifuged at
5200× g and the supernatant was digested with 2 U/μl of RNase I (Thermo Sci-
entiﬁc) for 40 min at room temperature. Lysates were fractionated on a linear
sucrose gradient (7–47%) using the SW-41Ti rotor at 28,3807×g for 2 h. Fractions
enriched in ribosomes were pooled and treated with proteinase K (Roche) in a 1%
SDS solution. Released RNA fragments were puriﬁed using Trizol. For library
preparation, RNA was gel-puriﬁed on a denaturing 10% polyacrylamide urea (7M)
gel. A section corresponding to 30–33 nucleotides was excised, eluted, and ethanol
precipitated. The resulting fragments were 3′-dephosphorylated using T4 PNK
(New England Biolabs) for 4 h at 37 °C in 2-(N-morpholino)ethanesulfonic acid
(MES) buffer (100 mM MES–NaOH, pH 5.5, 10 mM MgCl2, 10 mM β-mercap-
toethanol, 300 mM NaCl). 3′ adaptor was added with T4 RNA ligase 1 (New
England Biolabs) for 2.5 h at 37 °C. Ligation products were 5′-phosphorylated with
T4 polynucleotide kinase for 30 min at 37 °C. 5′ adaptor was added with T4 RNA
ligase 1 for 18 h at 22 °C. The resulting fragments were incubated with a biotiny-
lated ribosomal RNA (rRNA) oligo pool (10 μM each, see Supplementary Data 9)
for 10 min at 37 °C, upon short denaturation at 95–100 °C for 1 min, followed by
rRNA depletion using MyOne Streptavidin C1 DynaBeads (Thermo Fisher Sci-
entiﬁc). The resulting rRNA-depleted fragments were reverse transcribed using the
SuperScript III cDNA synthesis kit. Samples were PCR-ampliﬁed for 15 cycles and
the products were multiplexed and sequenced on an Illumina HiSeq 2500 platform.
Matched total mRNA samples were processed as described in the previous section.
Pre-processing and genome mapping. Reads from Polysomal RNA sequencing
and matched mRNA sequencing libraries11 were processed as following. The ﬁrst
5′ nucleotide was removed using seqtk (https://github.com/lh3/seqtk), as it fre-
quently represents an untemplated addition from reverse transcription40. For
ribosome footprinting libraries, adapters were trimmed using fastq-mcf (https://
code.google.com/p/ea-utils/), and only clipped reads of a minimum length of 20
nucleotides were kept. rRNA and tRNA contamination was computationally
removed by mapping to tRNA and rRNA references using Bowtie241 and collecting
only unaligned reads. These reads were then aligned to the mouse mm10 reference
genome and to spliced transcripts using Tophat v2.0.1142. Only primary align-
ments with mapping quality (mapqual) ≥ 10 were retained. For ribosome foot-
printing, only reads aligned to the CDS and excluding those aligned to the ﬁrst 15
and last ﬁve codons due to the accumulation of ribosomes43,44 were considered for
feature counting. For reads from mRNA sequencing, feature counting was per-
formed considering reads aligned to exons.
Analysis of differentially expressed transcripts. DESeq245 was applied on the
mRNA datasets to identify differentially expressed transcripts between R98S and
WT (FDR < 0.1). The genes with consistent and signiﬁcant differential expression
in all three available mRNA datasets (supplementary mRNA, mRNA matched to
the polysome proﬁling, and mRNA matched to ribosome footprinting) were
considered for enrichment analyses and used as input for iRegulon14 to identify
transcription factors that may act as key regulators of the identiﬁed downregulated
and up-regulated mRNAs.
Metagene analyses around start and stop codons. Metagene proﬁles of ribo-
some footprint densities were generated for each sample around the start and stop
codons, including 100 bp upstream and downstream. Only transcripts with at least
256 aligned ribosome footprints and having a known 5′ UTR and 3′ UTR were
considered. Each read was represented by the most 5′ mapped nucleotide and read
counts per position were averaged over all transcripts and normalized for the
number of mapped reads.
Ribosome footprint density proﬁles. Ribosome footprint density proﬁles along
the mRNAs of interest were generated using alignments from transcriptome
mapping. The position of the most 5′ mapped nucleotide for each read is shown.
The number of ribosome footprints per position was normalized for the tran-
scriptome mapped library size and averaged between three replicates per condition.
Transcriptome mapping was performed using a custom non-redundant tran-
scriptome containing only the longest isoform of validated or manually annotated
protein-coding transcripts for each gene. The Bowtie46 mapping program was used
in three steps with progressively lower stringency in order to optimize the number
of mapped reads. First, only uniquely aligned reads with no mismatches in the seed
were retained; then, remaining reads were mapped again and uniquely mapping
reads with one mismatch in the seed were retained; ﬁnally, the remaining
unmapped reads were mapped allowing for one mismatch in the seed and non-
unique alignment.
TE calculation. The abundance of ribosome footprints of an mRNA depends on
the translation rate and on the level of mRNA expression. Therefore, TE is com-
monly estimated as the ratio between ribosome footprint counts (ribosome pro-
tected fragments, RPF) and expressed mRNA counts (mRNA) (TE= RPF/mRNA).
Differences in TE between R98S and WT conditions were calculated as TE(R98S)/
TE(WT). The Babel R package16 was used to estimate the statistical signiﬁcance of
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TE differences between WT and R98S. TE calculations on polysomal RNA
sequencing were described previously11.
Enrichment analyses. Enrichment for pathways (KEGG) or Gene Ontology
functional categories (GO Biological Process Non-Redundant) was calculated using
WebGestalt47 with a minimum of two genes and with p-adj < 0.1 (hypergeometric
test with Benjamini–Hochberg correction) for genes showing signiﬁcant changes in
transcription or TE between the RPL10 R98S and WT condition.
Cell cultures. RPL10 R98S positive leukemia cells only express mutant RPL105. To
mimic this, Ba/F3 cells (DSMZ) were transduced with retroviral vectors encoding
human WT or R98S RPL10 cDNAs and endogenously expressed Rpl10 was
knocked down with an Rpl10-targeting shRNA. Liquid cultures were established
from single cell colonies grown in Clonacell-TCS medium (Stemcell technologies)
followed by selection of cultures with ≥ 90% knock-down of endogenous Rpl10 as
determined by qPCR. Expression of RPL10 R98S and knock-down of endogenous
Rpl10 were conﬁrmed by Sanger sequencing of cDNA. Cells derived from three
monoclonal RPL10 WT or R98S-expressing Ba/F3 cultures were used for all the
experiments. For Ba/F3 media exchange experiments, cells were cultured for 5 days
without medium exchange or sub-culturing of the cells (overgrowth condition). At
that point, half of the culture media was replaced by either RPL10 WT-conditioned
media or RPL10 R98S-conditioned media in the presence or absence of 20 μM
serine for 2 days, after which the cultures were analyzed for viable cell counts on a
MACSQuant VYB (Miltenyi) by propidium iodide (PI) exclusion.
To set up hematopoietic cell cultures from lineage negative bone marrow cells,
Rpl10 R98S conditional knock-in mice11 were crossed to Mx1-Cre C57Bl/6 mice
(B6.Cg-Tg(Mx1-cre)1Cgn/J strain Jackson Laboratories). Lineage-negative cells
were isolated (EasySep Mouse Hematopoietic Progenitor Cell enrichment kit,
Stemcell Technologies) from 6 to 8 weeks old Mx1-Cre Rpl10cKI R98S and from
Rpl10cKI R98S control mice. Cells were plated at 2000 cells/ml in Methocult GF
M3534 medium (Stemcell Technologies) containing 1250 units/ml of IFNβ (R&D
systems) to induce recombination of the conditional Rpl10 R98S allele. After
10–15 days, cells were replated in fresh Methocult GF M3534 medium or analyzed
as indicated. Expression of the R98S mutation upon Cre recombination was
conﬁrmed by Sanger sequencing of cDNA of the region encoding Rpl10 R98.
Jurkat, DND41, RPMI8402, and KE37 T-ALL cell lines were obtained from
Leibniz-Institute DSMZ and grown in RPMI-1640 with 20% fetal calf serum. Used
cells were mycoplasma negative. RPMI8402 and DND41 were authenticated by
conﬁrming unique NOTCH1 mutational status.
Jurkat cells carrying the RPL10 R98S mutation were generated by CRISPR/Cas9
genome editing. Jurkat cells were transduced with lentiCRISPR-Cas9, a lentiviral
Cas9 encoding plasmid. These Jurkat cells were then electroporated (6 square wave
pulses, 0.1 ms interval, 175 V) with a pX321 vector48 containing an RPL10
targeting gRNA (5′-TCTTGTTGATGCGGATGACG-3′) and with a 127-nt donor
oligo encoding the RPL10 R98S allele, as well as three silent mutations to avoid re-
recognition and cutting by the gRNA-Cas9 complex (5′-CCTGTCAGCCCCAGC
ACAGGACAACATCTTGTTAATGCTGATCACGTGAAAGGGGTGGAGCCGC
ACCCGGATATGGAAGCCATCTTTGCCACAACTTTTTACCATGTACTTATT
GGCACAAATTCGGGCA-3’; Integrated DNA Technologies). Following
electroporation, cells were incubated for 48 h in the presence of 500 nM SCR7
(Sigma-Aldrich), followed by single cell sorting (BD FACSAria I) into 96-well
plates. Growing clones were expanded and screened for the desired modiﬁcation
using a PCR approach with primers distinguishing the WT from the R98S allele
(Fw_WT: 5′-CTTCCACGTCATCCGCATC-3′; Fw_R98S: 5′-CCTTTCACGTGAT
CAGCATT-3′; Rev_WTandR98S: 5′-GCTCTGATAAAATAATGCAA GCCTA-
3′). Finally, RPL10 mutational status was conﬁrmed by Sanger sequencing.
Lentiviral vectors. shRNA sequences targeting PSPH (#1 ATTCTACTTTAACG
GTGAATA; #2 AGTCGCCTACAGGAGCGAAAT) or scrambled control were
inserted into a pLKO1-mCherry vector (Supplementary Fig. 12A). Lentiviral par-
ticles were generated by co-transfection of the pLKO1-mCherry plasmids with
packaging plasmid psPAX2 and the envelope plasmid pMD2.G (VSV-G) into
Hek293T cells using GeneJuice Transfection Reagent (Merck Millipore). Leukemic
cells were incubated overnight with lentiviral supernatants after which stably
transduced cells were expanded and injected into NSG mice. Transduction efﬁ-
ciencies reached above 80% (Supplementary Fig. 12B).
13C Tracer analysis. Labeling experiments were performed in glucose-free RPMI
supplemented with 13C6-glucose to a ﬁnal concentration of 11.1 mM and with 10%
dialyzed serum for 48 h. 13C6-glucose tracer was purchased from Sigma-Aldrich.
Fifty milliliters of falcon tubes with methanol 60% and 10 mM ammonium acetate
were precooled in a dry ice–ethanol bath (−40 °C) for 20 min. Cells in suspension
were transferred with a 1000 μl pipette from the culture plates to 15 ml falcon tubes
and pelleted by centrifugation (300×g, 3 min, room temperature) to remove excess
of medium. Medium was aspirated and the remaining cell pellet was immediately
added to the 50 ml falcon tube containing 5 ml of the quenching solution at
−40 °C. Cells were pelleted by centrifugation (600×g, 30 s, room temperature) and
the supernatant was removed by quickly inverting the tube. The cell pellet was
washed a second time with quenching solution (−40 °C). After the second wash,
the cell pellet was stored at −80 °C.
Metabolites extraction was achieved by a cold two-phase
methanol–water–chloroform extraction. The samples were resuspended in 800 µl
of precooled 60% methanol followed by addition of 500 µl of precooled chloroform.
Samples were vortexed for 10 min at 4 °C and then centrifuged (max. speed, 10
min, 4 °C). The methanol–water phase containing polar metabolites was separated
and dried using a vacuum concentrator at 4 °C overnight. The samples were stored
at −80 °C. Polar metabolites were analyzed by GC–MS and LC–MS.
For GC–MS measurement, polar metabolites were derivatized with 20 mgml−1
methoxyamine in pyridine for 90 min at 37 °C and subsequently with N-(tert-
butyldimethylsilyl)-N-methyl-triﬂuoroacetamide, with 1% tert-butyldimethyl
chlorosilane for 60 min at 60 °C. Metabolites were measured with a 7890A GC
system (Agilent Technologies) combined with a 5975C Inert MS system (Agilent
Technologies). One microliter of sample was injected onto a DB35MS column with
a split ratio1 to 3, and an inlet temperature of 270 °C. The carrier gas was helium
with a ﬂow rate of 1 ml min−1. For the measurement of polar metabolites, the GC
oven was held at 100 °C for 1 min and then ramped to 105 °C at 2.5 °C/min and
with a gradient of 2.5 °C/min ﬁnally to 320 °C at 22 °C/min. The MS system was
operated under electron impact ionization at 70 eV and a selected-ion monitoring
(SIM) mode was used for the measurement of metabolites. Mass distribution
vectors were extracted from the raw ion chromatograms using a custom Matlab
M-ﬁle, which applies consistent integration bounds and baseline correction to each
ion. Data were corrected for naturally occurring isotopes49.
For the detection of metabolites by LC–MS, a Dionex UltiMate 3000 LC System
(Thermo Scientiﬁc) with a thermal autosampler set at 4 °C, coupled to a Q Exactive
Orbitrap mass spectrometer (Thermo Scientiﬁc) was used for the separation of
polar metabolites. After the injection of 15 μl of sample, the separation of
metabolites was achieved with a ﬂow rate of 0.25 ml/min, at 40 °C, on a C18
column (Acquity UPLC HSS T3 1.8 µm 2.1 × 100 mm). A gradient was applied for
40 min (solvent A: 0 H2O, 10 mM tributyl-amine, 15 mM acetic acid—solvent B:
Methanol) to separate the targeted metabolites (0 min: 0%B, 2 min: 0%B, 7 min:
37%B, 14 min: 41%B, 26 min: 100%B, 30 min: 100%B, 31 min: 0%B; 40 min: 0%B).
The MS operated in negative full scan mode (m/z range: 70–1050 and 300–800
from 8 to 25 min) using a spray voltage of 4.9 kV, capillary temperature of 320 °C,
sheath gas at 50.0, auxiliary gas at 10.0. Data was collected using the Xcalibur
software (Thermo Scientiﬁc) and analyzed with Matlab for the correction of natural
abundance and to determine the isotopomer distribution, using the same method
as described above for the analysis of GC–MS data.
Formate assays. Cellular formate levels were determined according to manu-
facturer’s protocol (Formate assay, Biovision). In this assay, formate is oxidized and
resulting NAD(P)H levels generate a colored product that was measured on a
VICTOR platereader (Perkin Elmer) at λ= 450 nm to quantify formate. Correction
for protein input was done using the Bradford method and readings of background
NAD(P)H levels were subtracted from all samples.
Flow cytometry. Proliferation was measured by counting viable cells over time
(growth curve), and cell cycle was analyzed by bromodeoxyuridine (BrdU)
incorporation and/or propodium iodide (PI) staining. BrdU incorporation was
measured following 70% EtOH ﬁxation, HCl denaturation, EDTA neutralization,
and BrdU-FITC antibody staining (Thermo Fisher). PI cell cycle analysis required
70% EtOH ﬁxation followed by 1 h incubation with PI solution (25 μg/mL PI, 300
μg/ml RNAse, 0.05% Triton-X100, Sigma Aldrich) at 37 °C. Protein synthesis was
assessed using O-propargyl-puromycin (OPP) incorporation according to manu-
facturer’s protocol with the adaptation of methanol ﬁxation (Click-iT, Thermo
Fisher). All samples were measured using a MACSQuant VYB (Miltenyi) ﬂow
cytometer and FlowJo software.
Metabolite measurements. Plasma samples collected from T-ALL grafted NSG
mice at disease end stage were analyzed by ion chromatography to determine
metabolite amounts in the blood plasma. Conditioned media from cell cultures
were ﬁltered (0.45 μm) and analyzed by ion chromatography to measure metabolite
leftovers in the media of cells in overgrowth condition. Ion chromatography was
performed according to diagnostics criteria at Laboratory Medicine, University
Hospitals Leuven, UZ Leuven, Belgium.
Effects of serine/glycine on stromal cells and macrophages. Primary C57BL/6
mouse cells were extracted from the bone marrow (bone marrow stromal cells) by
one day adherence to the culture ﬂasks and myeloid macrophages were extracted
by peritoneal lavage. Recovered cells were plated into 96-well dishes in six technical
repeats per condition. Cells were cultured in RPMI-1640 containing 5 µM serine
and 85 µM glycine with or without the addition of 400 μM serine or glycine, and
effects on cell survival were monitored by imaging adhering cells on an IncuCyte
Zoom system (Essen Bioscience), as apoptotic cells shrink and detach.
Immunoblotting. Cells were lysed (cell lysis buffer, Cell Signaling Technology) and
denatured in 1x Laemmli sample buffer (Bio-rad) containing 2-mercaptoethanol
(Sigma Aldrich). Proteins were separated on Criterion Tris-Glycine eXtended gels
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(Bio-rad), transferred to PVDF membranes using a Trans-Blot Turbo system (Bio-
rad), incubated with primary antibodies targeting PSPH (Bioconnect, 14513-1-AP,
1:1000), phospho-CDK2 (4539, 1:1000) or Helios (42427, 1:1000) (Cell Signaling
Technology), and with secondary Goat Anti-Rabbit (31462, 1:2000) or Goat Anti-
Mouse (31432, 1:2000) IgG-HRP antibody (ThermoFischer Scientiﬁc) or near infra-
red anti-Mouse (5470, 1:1000) or anti-Rabbit (5151, 1:1000) antibodies (Cell Signaling
Technology). Proteins were visualized using ﬂuorescent secondary antibodies or
chemiluminescence on an Azure C600 (Azure Biosystems). Quantiﬁcation was per-
formed using LI-COR Image Studio Lite software version 5.2. Vinculin (V9131,
1:4000) or β-actin (A 1978, 1:4000) (Sigma Aldrich) were used to normalize for
protein input. Immunoblots were repeated at least three times and representative blots
are shown in the ﬁgures and in full size in Supplementary Fig. 18.
Polysomal qRT-PCR analysis. Cell lysates from three Ba/F3 RPL10 WT and three
R98S clones were applied on a sucrose gradient and centrifuged in order to get a
distribution of monosomes and polysomes. An amount of 15 × 106 cells were
pelleted by centrifugation (5 min, 470×g) and were lysed in ice-cold 100 mM KCl,
20 mM Hepes (Life technologies), 10 mM MgCl2, 1 mM DTT, 1% sodium deox-
ycholate, 1% NP-40 (Tergitol solution, Sigma-Aldrich), 100 µg ml−1 cyclohex-
imide, 1% Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich), 1% Phosphatase
Inhibitor Cocktail 3 (Sigma-Aldrich), 1% Protease Inhibitor Cocktail (Sigma-
Aldrich), 100 Uml−1 RNasin (Promega). After 10 min incubation on ice, lysates
were centrifuged 5 min at 15,871×g and the resulting supernatant was loaded onto
10–60% sucrose density gradients (100 mM KCl, 20 mM Hepes, 10 mM MgCl2).
Gradients were then centrifuged in a SW40Ti rotor (Beckman Coulter) at
28,3807×g for 150 min and polysomal fractions were monitored through a live
OD254 nm measurement on a BioLogic LP System (Bio-Rad). Eleven fractions of
equal volume were collected. For technical reasons, the three fractions corre-
sponding to the highest polysomes were subsequently combined and considered as
one fraction. RNA was extracted from equal volumes of the ﬁve remaining frac-
tions using the phenol–chlorophorm method including an extra washing step with
70% ethanol followed by cDNA synthesis. On each fraction, qRT-PCR was per-
formed for Psph in quadruplicate.
Quantitative RT-PCR. RNA was extracted using the RNeasy kit (Qiagen) followed
by cDNA synthesis of 4 μg RNA using random hexamer primers, and a mix of
ribonuclease inhibitors, dNTPs, and GoScript reverse transcriptase (Promega).
PSPH mRNA expression together with GAPDH or Hprt as a reference gene, were
analyzed in triplicates using SYBR Green-based qRT-PCR on a CFX Connect
instrument (Bio-rad laboratories). Relative mRNA expression from four technical
repeats was determined using the ΔΔCt method (primer sequences, Supplementary
Data 10).
T-ALL patient samples. This study was approved by the ethics committees of UZ/
KU Leuven and Universiteit Gent (S54608 and S59975). After getting written
informed consent, the mononuclear cell fraction of bone marrow from pediatric T-
ALL patients was obtained and the cells were xenografted into 6–8 weeks old NSG
mice. The public R2: Genomics Analysis and Visualization Platform was used to
explore mRNA expression levels in pediatric T-ALL and normal bone marrow
CD34+ control samples (dataset: Meijerink, MAS5.0-u133p2, this study includes
117 pediatric T-ALL and 7 normal bone marrow control samples).
Xenografting in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. NSG animal
experiments were approved by the KU Leuven animal ethics committee (ECD;
approval P179/2015). Human T-ALL patient samples were engrafted by tail vein
injections of 106 cells. Blood samples were obtained every 2 weeks from the facial
vein. Cells were stained for 30 min with 4 μl human CD45 antibody (eBioscience)
and measured by ﬂow cytometry. Animals reaching > 90% human CD45 expressing
cells in their peripheral blood were sacriﬁced. Terminal cardiac bleeding was
performed under pentobarbital (150 mg/kg) anesthesia to obtain blood plasma.
Human T-ALL patient-derived xenograft (PDX) X12, KE37, and RPMI8402 cells
were transduced with scrambled or shRNAs targeting PSPH (shPSPH) and
engrafted by tail vein injection of 1*106 cells.
Statistics. All statistical analyses were performed using R or IBM SPSS 23 (IBM
Analytics) softwares. A two-sided Wald test was applied by DESeq2 to analyze
differentially expressed transcripts. p-values were corrected for multiple compar-
isons by the Benjamini–Hochberg method. We used the two-sided z-test in to
analyze differences in TE. Obtained p-values were corrected for multiple com-
parisons by the Benjamini–Hochberg method. A t-test was used by Scaffold4 for
the analysis of differentially expressed proteins, as previously described11.
Enrichment analyses performed with WebGestalt were based on a hypergeometric
test with Benjamini–Hochberg correction.
A two-tailed Student’s t-test was used to compare RPL10 WT and RPL10 R98S
conditions for all in vitro and in vivo measurements based upon Levene’s Test for
Equality of Variances. For the comparisons between scrambled controls and
shPSPH cells, Student’s t-tests were used to compare groups individually. The
proliferation index was calculated by taking the mean out of at least three
measurements for the fold changes in growth comparing scrambled controls and
shPSPH cell cultures. The boxplots present ﬁve sample statistics; the minimum, the
lower quartile, the median, the upper quartile, and the maximum, all summarized
in a visual display using IBM SPSS software. Whiskers/inner fences are deﬁned
based upon the distribution of the data points, up to a maximum of 1.5 times the
height of the box. Outliers are presented in each plot, when exceeding the whiskers.
Rounded outliers lay in the range of 1.5–3 times the height of the box and asterisks
or stars are extreme outliers that have values more than three times the height of
the boxes.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The quantitative mass spectrometry dataset has been described previously (PRIDE
identiﬁer PXD005995)11, as well as polysomal RNA sequencing and its associated mRNA
sequencing (GEO accession GSE106528)11 and a supplementary mRNA sequencing
dataset (GEO accession GSE106528)12. Ribosome footprinting and matched mRNA
sequencing (GEO accession GSE106528) have not been described previously. All datasets
are listed in Supplementary Data 11. Number of reads and reproducibility of the high-
throughput sequencing libraries are also provided in Supplementary Table 11. These
datasets are linked to Figs. 1, 2 and 3 and Supplementary Figs. 1–4. There are no
restrictions on data availability.
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